The common illness known as overactive bladder (OAB) has a negative impact on quality of life. More severe morbidity than that experienced by OAB patients who are continent is conferred when there is urgency incontinence. The main course of action for OAB and urgency incontinence is a combination of behavioral measures and antimuscarinic drug therapy. The optimum antimuscarinic medication should effectively treat OAB symptoms with the fewest possible negative effects.; it should be available as a once-daily sustained release formulation and in dosage strength that allows easy dose titration for the majority of sufferers. Solifenacin succinate was launched in 2005, and has been shown in both short and long term clinical trials to fulfill these requirements. A competitive M3 receptor antagonist with a lengthy half-life (45-68 hours), solifenacin. It comes in two dose strengths: a once-daily 5 or 10 mg pill [1].
